Current treatment strategies for hepatorenal syndrome.
作者信息
Solà Elsa, Guevara Mónica, Ginès Pere
机构信息
From the Liver Unit, Hospital Clínic, University of Barcelona School of Medicine; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd); and Instituto Reina Sofía de Investigación Nefrológica (IRSIN), Barcelona, Spain.
出版信息
Clin Liver Dis (Hoboken). 2013 Jun 21;2(3):136-139. doi: 10.1002/cld.209. eCollection 2013 Jun.
Abstract
摘要
相似文献
1
Current treatment strategies for hepatorenal syndrome.肝肾综合征的当前治疗策略。
Clin Liver Dis (Hoboken). 2013 Jun 21;2(3):136-139. doi: 10.1002/cld.209. eCollection 2013 Jun.
2
Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.比较药物策略治疗 1 型肝肾综合征的疗效：系统评价和网络荟萃分析。
Lancet Gastroenterol Hepatol. 2017 Feb;2(2):94-102. doi: 10.1016/S2468-1253(16)30157-1. Epub 2016 Dec 2.
3
Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies.肝硬化患者的肾衰竭：肝肾综合征和肾脏支持策略。
Curr Opin Anaesthesiol. 2010 Apr;23(2):139-44. doi: 10.1097/ACO.0b013e32833724a8.
4
Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.肝硬化肝肾综合征患者同时使用全身性血管收缩剂与多巴胺或前列环素后的肾脏及神经激素变化
J Hepatol. 1996 Dec;25(6):916-23. doi: 10.1016/s0168-8278(96)80297-2.
5
Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis.肝硬化患者急性静脉曲张出血和肝肾综合征的诊断和初步处理建议。
Dig Dis Sci. 2019 Jun;64(6):1419-1431. doi: 10.1007/s10620-018-5448-y. Epub 2019 Jan 25.
6
Terlipressin versus other vasoactive drugs for hepatorenal syndrome.特利加压素与其他血管活性药物治疗肝肾综合征的比较
Cochrane Database Syst Rev. 2017 Sep 27;9(9):CD011532. doi: 10.1002/14651858.CD011532.pub2.
7
Population Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998-2011.1998 - 2011年基于人群的肝肾综合征诊断住院发病率趋势
Int J Nephrol. 2016;2016:8419719. doi: 10.1155/2016/8419719. Epub 2016 Apr 6.
8
Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.米多君预防2型肝肾综合征复发：一项病例对照研究。
Dig Liver Dis. 2009 Apr;41(4):298-302. doi: 10.1016/j.dld.2008.09.014. Epub 2009 Jan 20.
9
10
Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis.肝硬化肝肾综合征的血管收缩剂治疗
Curr Pharm Des. 2006;12(35):4637-47. doi: 10.2174/138161206779010413.
引用本文的文献
1
INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion.INFUSE：一项多中心、开放标签、关于持续输注特利加压素治疗肝肾综合征-急性肾损伤的协作研究的原理与设计。
Contemp Clin Trials Commun. 2023 Oct 5;36:101211. doi: 10.1016/j.conctc.2023.101211. eCollection 2023 Dec.
2
A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug.以特利加压素为主要关注点的肝肾综合征新兴治疗方法的系统评价：一种近期获美国食品药品监督管理局批准的药物
Cureus. 2023 Jul 24;15(7):e42367. doi: 10.7759/cureus.42367. eCollection 2023 Jul.
本文引用的文献
1
Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice.肝肾综合征、MELD 评分与肝移植：一个不断演变的问题，对临床实践具有重要意义。
J Hepatol. 2012 Nov;57(5):1135-40. doi: 10.1016/j.jhep.2012.06.024. Epub 2012 Jun 26.
2
Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis.尿中性粒细胞明胶酶相关载脂蛋白预测肝硬化患者死亡率并识别急性肾损伤。
Dig Dis Sci. 2012 Sep;57(9):2362-70. doi: 10.1007/s10620-012-2180-x. Epub 2012 May 6.
3
Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis.尿中性粒细胞明胶酶相关脂质运载蛋白作为肝硬化患者肾功能损害鉴别诊断的生物标志物。
J Hepatol. 2012 Aug;57(2):267-73. doi: 10.1016/j.jhep.2012.03.015. Epub 2012 Apr 17.
4
Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis.肝肾综合征：肝硬化导致肾衰竭的一种严重但可治疗的病因。
Am J Kidney Dis. 2012 Jun;59(6):874-85. doi: 10.1053/j.ajkd.2011.12.032. Epub 2012 Apr 4.
5
Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.去甲肾上腺素与特利加压素治疗肝肾综合征的随机对照研究。
J Hepatol. 2012 Jun;56(6):1293-8. doi: 10.1016/j.jhep.2012.01.012. Epub 2012 Feb 6.
6
Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure.分段式血浆分离吸附对慢加急性肝衰竭患者生存的影响。
Gastroenterology. 2012 Apr;142(4):782-789.e3. doi: 10.1053/j.gastro.2011.12.056. Epub 2012 Jan 13.
7
Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.肝肾综合征患者在肝移植前使用血管收缩剂和白蛋白治疗的肝移植结局。
Transplantation. 2011 May 27;91(10):1141-7. doi: 10.1097/TP.0b013e31821690bf.
8
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.欧洲肝脏研究学会肝硬化腹水、自发性细菌性腹膜炎和肝肾综合征管理临床实践指南
J Hepatol. 2010 Sep;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004. Epub 2010 Jun 1.
9
Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.肝性肾病综合征血管收缩药物随机试验的系统评价。
Hepatology. 2010 Feb;51(2):576-84. doi: 10.1002/hep.23286.
10
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation.第一届国际肝移植学会肝移植肾功能不全专家小组共识会议报告
Liver Transpl. 2009 Nov;15(11):S1-34. doi: 10.1002/lt.21877.
Zotero 插件